Phase 2 Lymphoma Trial, Recruiting NCT07496229 Sponsor: Dizal Pharmaceuticals Condition: Lymphoma
Back to Lymphoma

Phase 2 Lymphoma Trial, Recruiting

NCT07496229
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have given their written agreement to take part in the trial
  • People who are 18 years of age or older
  • People whose overall health and ability to carry out daily activities meets a certain minimum level, as measured by a standard medical scoring tool (confirm with trial site)
  • People who are expected to live for at least 12 weeks
  • People who have been diagnosed with a type of blood cancer called peripheral T-cell lymphoma (PTCL), confirmed by laboratory testing of tissue
  • People who have measurable signs of the disease that can be tracked during the trial
  • People whose bone marrow, organs (such as liver and kidneys), and overall body function meet the required health levels
  • People who are able to follow the trial's schedule and complete all required visits and procedures
  • People who are willing and able to use adequate contraception throughout their time in the trial

Who may not be able to join:

  • People who still have unresolved side effects from a previous treatment that are above a mild level
  • People whose lymphoma has spread to the brain or spinal cord
  • People who have not waited long enough after finishing other cancer treatments before joining this trial (confirm with trial site)
  • People whose use of steroid medicines does not meet the trial's specific requirements (confirm with trial site)
  • People who have had major surgery or a significant physical injury recently, or who have major surgery planned in the near future (confirm with trial site for specific timeframes)
  • People who have received a live vaccine recently (confirm with trial site for specific timeframe)
  • People who are unable to stop taking certain medications that are not permitted during the trial
  • People who need to take immune-suppressing medicines or certain biological medicines because of another health condition
  • People who have an active infection at the time of joining
  • People with serious heart or cardiovascular disease
  • People with a stomach or bowel condition that could affect how the study medicine is taken in or absorbed by the body
  • People who have a history of another type of cancer
  • People who are known to be allergic to the study medicine
  • People with other severe or poorly controlled illnesses
  • People who work at the trial site or are employed by the company sponsoring the trial, due to a conflict of interest
  • People who are pregnant or currently breastfeeding
  • People who are unable to follow the trial's procedures and requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-21-61097800

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Dizal Pharmaceuticals
Registry
ClinicalTrials.gov
Start date
15 April 2026
Est. completion
1 September 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Part A: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).; Part B: Complete Response Rate (CRR) According to Lugano 2014 by Investigators' Review

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov